Immune checkpoint inhibitor-related pneumonitis following discontinuation of pembrolizumab in a patient with advanced lung adenocarcinoma: a case report and literature review

Abstract Background Checkpoint inhibitor-related pneumonitis (CIP) is a rare but serious complication of immune checkpoint inhibitors (ICIs). While it typically occurs within the first few months of treatment, its onset after ICI discontinuation is relatively uncommon. This report presents a case of...

Cijeli opis

Bibliografski detalji

Glavni autori:	Huan Wang, Yuzhen Jin, Peng Liu, Jie Zhou, Na Fan, Mengjie Li
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2024-12-01
Serija:	BMC Pulmonary Medicine
Teme:	Lung adenocarcinoma Immune checkpoint inhibitors Checkpoint inhibitor-related pneumonitis Pembrolizumab
Online pristup:	https://doi.org/10.1186/s12890-024-03424-9
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!